Patients with locally advanced or metastatic HER2‐positive gastric cancer or gastroesophageal junction adenocarcinoma, who had previously undergone trastuzumab‐based therapy, were granted US FDA approval to receive T‐DXd on January 15, 2021.124. The gene discussed is ERBB2; the disease is gastric cancer.